 |
|
|
With health care reform initiatives, quality measurement, and requirements for much greater accountability to numerous stakeholder groups, new questions arise constantly that need to be answered with more depth and greater insight.
Healthcare companies operate in an industry having truly unique challenges like long product development life cycles, regulated environments of different countries, complex market dynamics, etc. Our reports help these organizations to make informed business decisions in this increasingly challenging business environment.
We specialize in high-level information processing and analysis, specific to the needs of Healthcare and related industries worldwide. These reports contain analytical as well as statistical information on Healthcare industry. We thoroughly analyze new vistas being opened by the strongly growing healthcare industry like Telemedicine, Healthcare IT, Medical Devices, Medical Tourism, Health Insurance, E Health and Hospital Services.
|
|
|
 |
| US Cancer Vaccine Market Analysis |
| Sep, 2012 | Pages : 135 |
| Merck and GSK are expected to continue to be undefeated market leaders in the prophylactic cancer segment as the launch of a new cancer vaccine is unlikely in the next 3 years...
read more |
|
Buy Now
US$ 1200.00
|
|
|
|
 |
| US Cardiac Device Market Analysis |
| Jul, 2012 | Pages : 75 |
| The market for cardiac medical devices in the US is one of the most prominent healthcare segments and it is likely to register a CAGR of around 9% during 2012-2015...
read more |
|
Buy Now
US$ 1000.00
|
|
|
 |
| Asia Pacific Pharma Sector Analysis |
| Jun, 2012 | Pages : 160 |
| Asia-Pacific pharma market is projected to grow at a CAGR of around 10% during 2012-2015, driven by changing regulatory environment, increasing disposable incomes among others...
read more |
|
Buy Now
US$ 1300.00
|
|
 |
| Cancer Generics Market Analysis |
| Jun, 2012 | Pages : 75 |
| The global cancer generics market is anticipated to grow at a compound annual rate of around 26% during 2011-2015 as many anti-cancer blockbuster drugs are on the verge of patent expiry...
read more |
|
Buy Now
US$ 1000.00
|
|
|
|
|
|
|
|
 |
|
|